2022
DOI: 10.3233/jnd-210741
|View full text |Cite
|
Sign up to set email alerts
|

An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy

Abstract: Background: Glucocorticoid steroids are standard of care in Duchenne Muscular Dystrophy (DMD) to slow disease course. Use of glucocorticoids in other muscular dystrophies, including Becker (BMD) and Limb Girdle (LGMD), has been less explored. Recently, preclinical studies conducted in DMD and LGMD mouse models showed once-weekly prednisone was associated with improved muscle performance without activation of muscle atrophy genes. Objective: To determine safety and tolerability of once-weekly prednisone in pati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(18 citation statements)
references
References 17 publications
0
13
0
Order By: Relevance
“…Human-relevant promising indications were recently reported by an exploratory open-label clinical trial in non-Duchenne patients with intermittent prednisone dosing at 7–9PM, which roughly corresponds to our mice injections in the early light-phase. In this 6-month-long study that compared patients at start and end of treatment, once-weekly prednisone improved performance at the 6-minute walk and 10-meters run tests without inducing the typical metabolic stress markers of chronic glucocorticoid dosing like hyperglycemia or fat mass gain [ 53 ]. Importantly for future translation, the extent to which circadian time-of-intake determines steroid effects on the immune system is still unknown and will need to be investigated.…”
Section: Discussionmentioning
confidence: 99%
“…Human-relevant promising indications were recently reported by an exploratory open-label clinical trial in non-Duchenne patients with intermittent prednisone dosing at 7–9PM, which roughly corresponds to our mice injections in the early light-phase. In this 6-month-long study that compared patients at start and end of treatment, once-weekly prednisone improved performance at the 6-minute walk and 10-meters run tests without inducing the typical metabolic stress markers of chronic glucocorticoid dosing like hyperglycemia or fat mass gain [ 53 ]. Importantly for future translation, the extent to which circadian time-of-intake determines steroid effects on the immune system is still unknown and will need to be investigated.…”
Section: Discussionmentioning
confidence: 99%
“…Several previous studies demonstrate that mdx mice treated daily with prednisolone exhibit more severe cardiac and skeletal muscle pathology ( 34 , 73 , 74 ). However, more recent studies support beneficial effects from weekly dosing in dystrophic mice and patients ( 8 , 75 ). Another study in which mdx mice were treated with prednisolone earlier from 2 to 4 weeks of age identified decreased expression of cellular adhesion molecules, and also showed an improvement in myofiber degeneration ( 76 ).…”
Section: Discussionmentioning
confidence: 99%
“…Human-relevant promising indications were recently reported by an exploratory open-label clinical trial in non-Duchenne patients with intermittent prednisone dosing at 7-9PM, which roughly corresponds to our mice injections in the early light-phase. In this 6-month-long study that compared patients at start and end of treatment, once-weekly prednisone improved performance at the 6-minute walk and 10-meters run tests without inducing the typical metabolic stress markers of chronic glucocorticoid dosing like hyperglycemia or fat mass gain [52]. Importantly for future translation, the extent to which circadian time-of-intake determines steroid effects on the immune system is still unknown and will need to be investigated.…”
Section: Discussionmentioning
confidence: 99%